Other

An ambulance transports the author to the Nebraska Medical Center in October. (Sait Serkan Gurbuz/Reuters)

THE ATLANTIC by Ashoka Mukpo                                                                          Feb. 12, 2015

Like the majority of patients taken to Western hospitals, I recovered from the disease—but health authorities are still struggling to figure out how to bring up the much-lower survival rate in West Africa.

...the 80-percent survival rate among patients who were evacuated to Western hospitals shattered the idea that an Ebola diagnosis spelled near-certain death. I know this all too well, as I’m one of those patients myself. In October, I contracted Ebola while covering the outbreak as a freelance journalist in Liberia. I was airlifted to a hospital in Nebraska, where aggressive treatment likely saved my life....
Read complete story.

http://www.theatlantic.com/health/archive/2015/02/why-didnt-ebola-kill-me/385335/

MEDICAL NEWS TODAY                                             Jan. 22, 2015

Ebola is a "zoonotic" disease: the virus starts out in animal populations - believed to be fruit bats - and then spills over into humans. Now, a new study that investigates landscape features of where spillover occurs suggests human population density and vegetation cover may be important factors.

The study is the work of two researchers from SUNY Downstate Medical Center in Brooklyn, NY, who write about their findings in the open-access journal PeerJ.

First author Michael G. Walsh, assistant professor of epidemiology and biostatistics in SUNY Downstate's School of Public Health, says they found significant interaction between density of human populations and the extent of green vegetation cover in the parts of Africa that have seen outbreaks of Ebola virus disease (EVD).

THE NEW ENGLAND JOURNAL OF MEDICINE                                                                                 Dec. 3, 2014
By Edward Cox, M.D., M.P.H., Luciana Borio, M.D., and Robert Temple, M.D.

...Studying investigational therapies for EVD presents scientific, practical, and ethical challenges. Not surprisingly, there has been substantial debate about the best and most appropriate study approaches.2,3 It is generally agreed that a trial with a concurrent control group, in which patients are randomly assigned to receive the test drug plus the best available supportive care (BASC) or to BASC alone, would be the most efficient and reliable way to evaluate the safety and effectiveness of candidate products.

 Some people in the health care community, however, have argued against such trials, urging instead use of a historical control — that is, making investigational drugs as widely available as their supply allows and then comparing mortality rates among treated patients with rates that would have been expected absent the drugs, on the basis of past experience with EVD.